209 related articles for article (PubMed ID: 34151131)
1. Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician.
Lee SM; Wages NA; Goodman KA; Lockhart AC
JCO Precis Oncol; 2021 Jan; 5():317-324. PubMed ID: 34151131
[TBL] [Abstract][Full Text] [Related]
2. Some notable properties of the standard oncology Phase I design.
Hather GJ; Mackey H
J Biopharm Stat; 2009; 19(3):543-55. PubMed ID: 19384695
[TBL] [Abstract][Full Text] [Related]
3. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
4. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
Wages NA; Tait C
J Biopharm Stat; 2015; 25(5):903-20. PubMed ID: 24904956
[TBL] [Abstract][Full Text] [Related]
5. Statistical designs for early phases of cancer clinical trials.
Guan S
J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
[TBL] [Abstract][Full Text] [Related]
6. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
7. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
Colin P; Micallef S; Delattre M; Mancini P; Parent E
Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
[TBL] [Abstract][Full Text] [Related]
8. R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials.
Guo W; Ji Y; Li D
J Biopharm Stat; 2019; 29(3):411-424. PubMed ID: 30744484
[TBL] [Abstract][Full Text] [Related]
9. Methodologic guidelines for the design of high-dose chemotherapy regimens.
Margolin K; Synold T; Longmate J; Doroshow JH
Biol Blood Marrow Transplant; 2001; 7(8):414-32. PubMed ID: 11569887
[TBL] [Abstract][Full Text] [Related]
10. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
Shimamura F; Hamada C; Matsui S; Hirakawa A
J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
[TBL] [Abstract][Full Text] [Related]
11. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
[TBL] [Abstract][Full Text] [Related]
13. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
14. Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design.
Yan D; Wages NA; Dressler EV
J Biopharm Stat; 2019; 29(2):333-347. PubMed ID: 30451068
[TBL] [Abstract][Full Text] [Related]
15. Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial.
Takeda K; Morita S
Pharm Stat; 2018 Jul; 17(4):372-382. PubMed ID: 29372582
[TBL] [Abstract][Full Text] [Related]
16. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
17. A product of independent beta probabilities dose escalation design for dual-agent phase I trials.
Mander AP; Sweeting MJ
Stat Med; 2015 Apr; 34(8):1261-76. PubMed ID: 25630638
[TBL] [Abstract][Full Text] [Related]
18. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
19. Applications of the partial-order continual reassessment method in the early development of treatment combinations.
Wages NA; Dillon PM; Portell CA; Slingluff CL; Petroni GR
Clin Trials; 2024 Jun; 21(3):331-339. PubMed ID: 38554038
[TBL] [Abstract][Full Text] [Related]
20. Dose optimization for cancer treatments with considerations for late-onset toxicities.
Biard L; Andrillon A; Silva RB; Lee SM
Clin Trials; 2024 Jun; 21(3):322-330. PubMed ID: 38591582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
